Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 6/20 | 1.00 |
| ▸ | TTBK2 | Q6IQ55 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741877 | 0.86 | TTBK1 (0.76) | TTBK1TTBK2HTTMEN1LMNA | |
| SCHEMBL8505023 | 0.86 | TTBK1 (0.75) | TTBK1TTBK2HTTLMNATSHR | |
| SCHEMBL23202913 | 0.82 | TTBK1 (0.69) | TTBK1TTBK2HTTLMNASMN1; SMN2 | |
| SCHEMBL23202860 | 0.81 | TTBK1 (0.67) | TTBK1TTBK2HTTLMNABTK | |
| SCHEMBL23202949 | 0.79 | TTBK1 (0.65) | TTBK1TTBK2HTTLMNABTK | |
| SCHEMBL31651184 | 0.79 | TTBK1 (0.65) | TTBK1TTBK2HTTLMNABTK | |
| SCHEMBL23409027 | 0.77 | TTBK1 (0.62) | TTBK1TTBK2BTKHDAC6 | |
| SCHEMBL29665587 | 0.77 | TTBK1 (0.62) | TTBK1TTBK2BTKHDAC6 | |
| SCHEMBL30485458 | 0.77 | TTBK1 (0.62) | TTBK1TTBK2BTKHDAC6 | |
| SCHEMBL28451436 | 0.77 | TTBK1 (0.62) | TTBK1TTBK2BTKHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102186479-A | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC | 2011-09-14 | — | — | CN | disclosed |
| EP-2320904-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010030757-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | TTBK1 2414/4885TTBK2 2307/4885HTT 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.